Cover Image
市場調查報告書

美國的MA (醫療事務) 部門的評估:HIV

Medical Affairs Reputations (US) [HIV]

出版商 FirstWord 商品編碼 509312
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的MA (醫療事務) 部門的評估:HIV Medical Affairs Reputations (US) [HIV]
出版日期: 2017年05月01日 內容資訊: 英文
簡介

本報告基於針對100名經手HIV治療藥的主要10項產品之各公司醫療事務 (MA) 團隊之美國傳染病專業醫生所進行的調查結果,彙整各公司團隊的效能及滿意度評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析。

對象企業·品牌

  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Isentress (raltegravir; Merck & Co.)
  • Prezcobix (darunavir/cobicistat; Janssen)
  • Prezista (darunavir; Janssen)
  • Reyataz (atazanavir; Bristol-Myers Squibb)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Viread (tenofovir disoproxil fumarate; Gilead)

調查·分析內容範例

  • 醫生的需求
    • 醫生使用您的醫療團隊之方式和頻率為何?
    • 他們認為最重要的服務是什麼?
    • 你應該多久聯繫一次?什麼管道最好?
  • MA團隊提供的內容
    • 醫生團隊互動的印象
    • 醫生在12個關鍵領域如何評價您的團隊績效和滿意度?
    • 與其他團隊的比較
  • 改善需要的地方等
目錄

Survey shows medical affairs teams must be more active and provide better information

Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those teams reached out to more than 70% of the infectious disease specialists we surveyed. Survey respondents also had a lot to say about how teams can improve the information they provide, and the way they provide it-feedback that can help teams build better relationships with doctors.

Find out what your team gets right, and where it's going wrong in Medical Affairs Reputations: HIV (US).

Comparing 10 major HIV treatments from Bristol-Myers Squibb, Gilead, Janssen, Merck & Co. , and ViiV Healthcare, this report reveals:

  • How infectious disease specialists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important, and what you can do to improve them.
  • How, and how often doctors want to meet with your team.

That's actionable information you can use to turn your team into one that doctors rely on.

Top Takeaways

  • Teams could be more active: Half of the surveyed teams interacted with less than 60% of the surveyed doctors in the past 6 months.
  • Doctors aren't getting all the information they need: They identified 3 ways teams can improve information provision, and highlighted 3 specific types of information they want more of.
  • Four teams have the same weakness: Find out which specific medical affairs service they all need to improve.
  • On the right frequency: The surveyed teams tend to be reaching out to doctors about as often as doctors would like. Just how often is that?
  • X factor: Which team earned a top-3 overall quality rating despite low performance and satisfaction scores on most individual services?
  • “Don't call us....”: Less than 10% for surveyed doctors prefer to be contacted by phone. So how should you get in touch when face-to-face meetings aren't possible?

Insight into Medical Affairs Teams for These HIV Treatments

  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Isentress (raltegravir; Merck & Co.)
  • Prezcobix (darunavir/cobicistat; Janssen)
  • Prezista (darunavir; Janssen)
  • Reyataz (atazanavir; Bristol-Myers Squibb)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Viread (tenofovir disoproxil fumarate; Gilead)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 10 medical affairs teams-answering important questions like:

What do doctors need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 100 US infectious disease specialists, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with HIV in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between April 3rd and 18th, 2017.

Back to Top